Review: Therapeutic advances in pulmonary arterial hypertension

Therapeutic Advances in Respiratory Disease

Volumn 2, Issue 4, 2008, Pages 249-265

  Boutet, K ^a   Montani, David ^a   Jaïs, Xavier ^a   Yaïci, Azzedine ^a   Sitbon, Oliver ^a   Simonneau, Gérald ^a   Humbert, Marc ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

combination therapy; endothelin receptor antagonists; lung transplantation; prostacyclin; pulmonary arterial hypertension; type 5 phosphodiesterase

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANESTHETIC AGENT; ANTICOAGULANT AGENT; BERAPROST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIAZOXIDE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ESTROGEN; GESTAGEN; HYDRALAZINE; ILOPROST; ISOPRENALINE; NIFEDIPINE; OXYGEN; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; SEDATIVE AGENT; SILDENAFIL; SITAXSENTAN; UNINDEXED DRUG; UNIPROST; WARFARIN;

ALTITUDE; ANESTHESIA; ARTICLE; BONE PAIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPRESSION THERAPY; CONTRACEPTION; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUSHING; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; HYPOTENSION; HYPOXIA; INFECTION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; LEG EDEMA; LEG PAIN; LIFESTYLE MODIFICATION; LIVER DYSFUNCTION; LOW DRUG DOSE; LUNG EDEMA; LUNG EMBOLISM; LUNG TRANSPLANTATION; MONOTHERAPY; NAUSEA; NOSE CONGESTION; OXYGEN THERAPY; PREGNANCY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY REHABILITATION; RISK FACTOR; SIDE EFFECT; SODIUM RESTRICTION; SYSTEMIC DISEASE; THROMBOSIS; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT; VASODILATATION; VOMITING;

ALGORITHMS; ALTITUDE; ANOXIA; ANTICOAGULANTS; CARDIOVASCULAR AGENTS; CONTRACEPTION; DIURETICS; ENZYME INHIBITORS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; HYPNOTICS AND SEDATIVES; LUNG TRANSPLANTATION; PREGNANCY; VASOCONSTRICTOR AGENTS;

EID: 68749099990     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465808094762     Document Type: Review

References (124)

1. Barst, R.J. (2005) Pdgf signaling in pulmonary arterial hypertension. J Clin Invest 115: 2691-2694.
2. Barst, R.J., Galie, N., Naeije, R., Simonneau, G., Jeffs, R., Arneson, C. et al. (2006a) Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 28: 1195-1203.
3. Barst, R.J., Langleben, D., Badesch, D., Frost, A., Lawrence, E.C., Shapiro, S. et al. (2006b) Treatment of pulmonary arterial hypertension with the selective endothelin-a receptor antagonist sitaxsentan. J Am Coll Cardiol 47: 2049-2056.
4. Barst, R.J., Langleben, D., Frost, A., Horn, E.M., Oudiz, R., Shapiro, S. et al. (2004) Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169: 441-447.
5. Barst, R.J., McGoon, M., McLaughlin, V., Tapson, V., Rich, S., Rubin, L. et al. (2003) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41: 2119-2125.
6. Barst, R.J., Rich, S., Widlitz, A., Horn, E.M., McLaughlin, V. and McFarlin, J. (2002) Clinical efficacy of sitaxsentan, an endothelin-a receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 121: 1860-1868.
7. Barst, R.J., Rubin, L.J., Long, W.A., McGoon, M.D., Rich, S., Badesch, D.B. et al. (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 334: 296-302.
8. Bjornsson, J. and Edwards, W.D. (1985) Primary pulmonary hypertension: a histopathological study of 80 cases. Mayo Clin Proc 60: 16-25.
9. Bonnin, M., Mercier, F.J., Sitbon, O., Roger-Christoph, S., Jais, X., Humbert, M. et al. (2005) Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology 102: 1133-1137; discussion 1135A-1136A.
10. Brenot, F. (1994) Primary pulmonary hypertension: case series from France. Chest 105: 33S-36S.
11. Castelain, V., Chemla, D., Humbert, M., Sitbon, O., Simonneau, G., Lecarpentier, Y. et al. (2002) Improvement of the pressure flow relationships of the pulmonary circulation in primary pulmonary hypertension after six weeks prostacyclin. Am J Respir Crit Care Med 165: 338-340.
12. Channick, R.N., Simonneau, G., Sitbon, O., Robbins, I.M., Frost, A., Tapson, V.F. et al. (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358: 1119-1123.
13. D'alonzo, G.E., Barst, R.J., Ayres, S.M., Bergofsky, E.H., Brundage, B.H., Detre, K.M. et al. (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective study. Ann Intern Med 115: 343-349.
14. Fagan, K.A., Oka, M., Bauer, N.R., Gebb, S.A., Ivy, D.D., Morris, K.G. et al. (2004) Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of rho-kinase. Am J Physiol Lung Cell Mol Physiol 287: L656-664.
15. Fahey, P.J., Utell, M.J., Condemi, J.J., Green, R. and Hyde, R.W. (1984) Raynaud's phenomenon of the lung. Am J Med 76: 263-269.
16. Fuster, V., Steele, P.M., Edwards, W.D., Gersh, B.J., McGoon, M.D. and Frye, R.L. (1984) Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70: 580-587.
17. Gaine, S.P. and Rubin, L.J. (1998) Primary pulmonary hypertension. Lancet 352: 719-725.
18. Galie, N., Badesch, D., Oudiz, R., Simonneau, G., McGoon, M.D., Keogh, A.M. et al. (2005a) Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46: 529-535.
19. Galie, N., Ghofrani, H.A., Torbicki, A., Barst, R.J., Rubin, L.J., Badesch, D. et al. (2005b) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353: 2148-2157.
20. Galie, N., Humbert, M., Vachiery, J.L., Vizza, C.D., Kneussl, M., Manes, A. et al. (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39: 1496-1502.
21. Ghofrani, H.A., Rose, F., Schermuly, R.T., Olschewski, H., Wiedemann, R., Kreckel, A. et al. (2003) Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 42: 158-164.
22. Ghofrani, H.A., Seeger, W. and Grimminger, F. (2005) Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353: 1412-1413.
23. Ghofrani, H.A., Wiedemann, R., Rose, F., Schermuly, R.T., Olschewski, H., Weissmann, N. et al. (2002) Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360: 895-900.
24. Girgis, R.E., Li, D., Zhan, X., Garcia, J.G., Tuder, R.M., Hassoun, P.M. et al. (2003) Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 285: H938-945.
25. Gomberg-Maitland, M., Barst, R., McLaughlin, V., Benza, R., Rich, S., Widlitz, A. et al. (2005a) Transition from intravenous epoprostenol to intravenous treprostinil for the treatment of pulmonary arterial hypertension (Pah). Proceedings of the American Thoracic Society 172(12): 1586-1589.
26. Gomberg-Maitland, M., McLaughlin, V., Gulati, M. and Rich, S. (2005b) Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol 96: 1334-1336.
27. Guilluy, C., Sauzeau, V., Rolli-Derkinderen, M., Guerin, P., Sagan, C., Pacaud, P. et al. (2005) Inhibition of rhoa/rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 146: 1010-1018.
28. Herve, P., Launay, J.M., Scrobohaci, M.L., Brenot, F., Simonneau, G., Petitpretz, P. et al. (1995) Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99: 249-254.
29. Higenbottam, T., Wheeldon, D., Wells, F. and Wallwork, J. (1984) Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1: 1046-1047.
30. Hoeper, M.M., Faulenbach, C., Golpon, H., Winkler, J., Welte, T. and Niedermeyer, J. (2004) Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 24: 1007-1010.
31. Hoeper, M.M., Schwarze, M., Ehlerding, S., Adler-Schuermeyer, A., Spiekerkoetter, E., Niedermeyer, J. et al. (2000) Long-term treatment of pulmonary hypertension with aerolized iloprost, a prostacyclin analogue. N Engl J Med 342: 1866-1870.
32. Hoeper, M.M., Taha, N., Bekjarova, A., Gatzke, R. and Spiekerkoetter, E. (2003) Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 22: 330-334.
33. Hosenpud, J.D., Bennett, L.E., Keck, B.M., Boucek, M.M. and Novick, R.J. (2001) The registry of the international society for heart and lung transplantation: eighteenth official report-2001. J Heart Lung Transplant 20: 805-815.
34. Hu, H., Sung, A., Zhao, G., Shi, L., Qiu, D., Nishimura, T. et al. (2006) Simvastatin enhances bone morphogenetic protein receptor type Ii expression. Biochem Biophys Res Commun 339: 59-64.
35. Hughes, J.D. and Rubin, L.J. (1986) Primary pulmonary hypertension. An analysis of 28 cases and a review of the literature. Medicine (Baltimore) 65: 56-72.
36. Humbert, M., Barst, R.J., Robbins, I.M., Channick, R.N., Galie, N., Boonstra, A. et al. (2004) Combination of bosentan with epoprostenol in pulmonary arterial hypertension: breathe-2. Eur Respir J 24: 353-359.
37. Humbert, M., Maitre, S., Capron, F., Rain, B., Musset, D. and Simonneau, G. (1998) Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med 157: 1681-1685.
38. Humbert, M., Sitbon, O. and Simonneau, G. (2004) Treatment of pulmonary arterial hypertension. N Engl J Med 351: 1425-1436.
39. Ishikura, K., Yamada, N., Ito, M., Ota, S., Nakamura, M., Isaka, N. et al. (2006) Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 70: 174-178.
40. Jones, K. (1996) Prostacyclin. In Peacock, A.J. (ed.) Pulmonary circulation. A handbook for clinicians. London: Chapman & Hall, 115-122.
41. Kandler, M.A., Von Der Hardt, K., Mahfoud, S., Chada, M., Schoof, E., Papadopoulos, T. et al. (2003) Pilot intervention: aerosolized adrenomedullin reduces pulmonary hypertension. J Pharmacol Exp Ther 306: 1021-1026.
42. Kao, P.N. (2005) Simvastatin treatment of pulmonary hypertension: an observational case Series. Chest 127: 1446-1452.
43. Kataoka, M., Satoh, T., Manabe, T., Anzai, T., Yoshikawa, T., Mitamura, H. et al. (2005) Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ J 69: 461-465.
44. Kerkela, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C. et al. (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12: 908-916.
45. Kerstein, D., Levy, P.S., Hsu, D.T., Hordof, A.J., Gersony, W.M. and Barst, R.J. (1995) Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 91: 2028-2035.
46. Kleiger, R.E., Boxer, M., Ingham, R.E. and Harrison, D.E. (1976) Pulmonary hypertension in patients using oral contraceptives. Chest 69: 143-147.
47. Kuhn, K.P., Byrne, D.W., Arbogast, P.G., Doyle, T.P., Loyd, J.E. and Robbins, I.M. (2003) Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 167: 580-586.
48. Laliberte, K., Arneson, C., Jeffs, R., Hunt, T. and Wade, M. (2004) Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 44: 209-214.
49. Lang, I., Gomez-Sanchez, M., Kneussl, M., Naeije, R., Escribano, P., Skoro-Sajer, N. et al. (2006) Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 129: 1636-1643.
50. Langleben, D., Hirsch, A.M., Shalit, E., Lesenko, L. and Barst, R.J. (2004) Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-a receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: A 1-year follow-up study. Chest 126: 1377-1381.
51. Laurent, S., Vanhoutte, P., Cavero, I., Chabrier, P.E., Dupuis, B., Elghozi, J.L. et al. (1996) The arterial wall: a new pharmacological and therapeutic target. Fundam Clin Pharmacol 10: 243-257.
52. Levine, S.M., Gibbons, W.J., Bryan, C.L., Walling, A.D., Brown, R.W., Bailey, S.R. et al. (1990) Single lung transplantation for primary pulmonary hypertension. Chest 98: 1107-1115.
53. Marcos, E., Adnot, S., Pham, M.H., Nosjean, A., Raffestin, B., Hamon, M. et al. (2003) Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 168: 487-493.
54. Mathai, S.C., Girgis, R.E., Fisher, M.R., Champion, H.C., Housten-Harris, T., Zaiman, A. et al. (2007) Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 29: 469-475.
55. McGoon, M.D. and Vlietstra, R.E. (1984) Vasodilator therapy for primary pulmonary hypertension. Mayo Clin Proc 59: 672-677.
56. McLaughlin, V.V., Genthner, D.E., Panella, M.M. and Rich, S. (1998) Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338: 273-277.
57. McLaughlin, V.V., Oudiz, R.J., Frost, A., Tapson, V.F., Murali, S., Channick, R.N. et al. (2006) Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174: 1257-1263.
58. McLaughlin, V.V., Presberg, K.W., Doyle, R.L., Abman, S.H., McCrory, D.C., Fortin, T. et al. (2004) Prognosis of pulmonary arterial hypertension*: Accp evidence-based clinical practice guidelines. Chest 126: 78S-92.
59. McLaughlin, V.V., Shillington, A. and Rich, S. (2002) Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106: 1477-1482.
60. McLaughlin, V.V., Sitbon, O., Badesch, D.B., Barst, R.J., Black, C., Galie, N. et al. (2005) Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25: 244-249.
61. Mendeloff, E.N., Meyers, B.F., Sundt, T.M., Guthrie, T.J., Sweet, S.C., De La Morena L. et al (2002) Lung transplantation for pulmonary vascular disease. Ann Thorac Surg 73: 209-217 discussion 217-209.
62. Moncada, S., Gryglewski, R., Bunting, S. and Vane, J.R. (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663-665.
63. Naeije, R. and Vachiery, J.L. (2001) Medical therapy of pulmonary hypertension. Conventional therapies. Clin Chest Med 22: 517-527.
64. Nagaoka, T., Fagan, K.A., Gebb, S.A., Morris, K.G., Suzuki, T., Shimokawa, H. et al. (2005) Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 171: 494-499.
65. Nagaya, N., Kyotani, S., Uematsu, M., Ueno, K., Oya, H., Nakanishi, N. et al. (2004) Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation 109: 351-356.
66. Nagaya, N., Miyatake, K., Kyotani, S., Nishikimi, T., Nakanishi, N. and Kangawa, K. (2003) Pulmonary vasodilator response to adrenomedullin in patients with pulmonary hypertension. Hypertens Res 26 Suppl: S141-146.
67. Nagaya, N., Shimizu, Y., Satoh, T., Oya, H., Uematsu, M., Kyotani, S. et al. (2002) Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension. Heart 87: 340-345.
68. Nagaya, N., Uematsu, M., Okano, Y., Satoh, T., Kyotani, S., Sakamaki, F. et al. (1999) Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 34: 1188-1192.
69. Nishimura, T., Faul, J.L., Berry, G.J., Vaszar, L., Qiu, D., Pearl, R.G. et al. (2002) Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 116(10): 1403-1408.
70. Nishimura, T., Vaszar, L.T., Faul, J.L., Zhao, G., Berry, G.J., Shi, L. et al. (2003) Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 108: 1640-1645.
71. Olschewski, H., Ghofrani, H.A., Schmehl, T., Winkler, J., Wilkens, H., Hoper, M.M. et al. (2000) Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German Pph study group. Ann Intern Med 132: 435-443.
72. Olschewski, H., Simonneau, G., Galie, N., Higenbottam, T., Naeije, R., Rubin, L.J. et al. (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347: 322-329.
73. Opitz, C.F., Wensel, R., Winkler, J., Halank, M., Bruch, L., Kleber, F.X. et al. (2005) Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 26(18): 1895-1902.
74. Oudiz, R.J., Widlitz, A., Beckmann, X.J., Camanga, D., Alfie, J., Brundage, B.H. et al. (2004) Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. Chest 126: 90-94.
75. Packer, M. (1985a) Therapeutic application of calcium-channel antagonists for pulmonary hypertension. Am J Cardiol 55: 196B-201B.
76. Packer, M. (1985b) Vasodilator therapy for primary pulmonary hypertension. Ann Intern Med 103: 258-270.
77. Packer, M., Greenberg, B., Massie, B. and Dash, H. (1982) Deleterious effects of hydralazine in patients with pulmonary hypertension. N Engl J Med 306: 1326-1331.
78. Packer, M., Medina, N., Yushak, M. and Wiener, I. (1984) Detrimental effects of verapamil in patients with primary pulmonary hypertension. Br Heart J 52: 106-111.
79. Panos, R.J. and Baker, S.K. (1996) Mediators, cytokines, and growth factors in liver-lung interactions. Clin Chest Med 17: 151-169.
80. Patterson, K.C., Weissmann, A., Ahmadi, T. and Farber, H.W. (2006) Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 145: 152-153.
81. Paul, G.A., Gibbs, J.S., Boobis, A.R., Abbas, A. and Wilkins, M.R. (2005) Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 60: 107-112.
82. Perros, F., Montani, D., Dorfmuller, P., Durand-Gasselin, I., Tcherakian, C., Le Pavec, J. et al. (2008) Platelet derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178(1): 81-88.
83. Petkov, V., Mosgoeller, W., Ziesche, R., Raderer, M., Stiebellehner, L., Vonbank, K. et al. (2003) Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111: 1339-1346.
84. Pielsticker, E.J., Martinez, F.J. and Rubenfire, M. (2001) Lung and heart-lung transplant practice patterns in pulmonary hypertension centers. J Heart Lung Transplant 20: 1297-1304.
85. Provencher, S., Herve, P., Jais, X., Lebrec, D., Humbert, M., Simonneau, G. et al. (2006a) Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 130: 120-126.
86. Provencher, S., Jais, X., Yaici, A., Sitbon, O., Humbert, M. and Simonneau, G. (2005) Clinical challenges in pulmonary hypertension: Roger S. Mitchell lecture. Chest 128: 622S-628S.
87. Provencher, S., Sitbon, O., Humbert, M., Cabrol, S., Jais, X. and Simonneau, G. (2006b) Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 27: 589-595.
88. Reeves, J.T., Groves, B.M. and Turkevich, D. (1986) The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis 134: 342-346.
89. Reitz, B.A., Wallwork, J.L., Hunt, S.A., Pennock, J.L., Billingham, M.E., Oyer, P.E. et al. (1982) Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 306: 557-564.
90. Rich, S., Dantzker, D.R., Ayres, S.M., Bergofsky, E.H., Brundage, B.H., Detre, K.M. et al. (1987) Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107: 216-223.
91. Rich, S., Dodin, E. and McLaughlin, V.V. (1997) Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application. Am J Cardiol 80: 369-371.
92. Rich, S., Kaufmann, E. and Levy, P.S. (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327: 76-81.
93. Rich, S. and Lam, W. (1983) Atrial septostomy as palliative therapy for refractory primary pulmonary hypertension. Am J Cardiol 51: 1560-1561.
94. Rich, S., Seidlitz, M., Dodin, E., Osimani, D., Judd, D., Genthner, D. et al. (1998) The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 114: 787-792.
95. Robbins, I.M., Christman, B.W., Newman, J.H., Matlock, R. and Loyd, J.E. (1998) A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension. Chest 114: 1269-1275.
96. Roskovec, A., Motanes, P. and Oakley, C. (1986) Factors that influence the outcome of primary pulmonary hypertension. Br Heart J 55: 449-458.
97. Rothman, A., Sklansky, M.S., Lucas, V.W., Kashani, I.A., Shaughnessy, R.D., Channick, R.N. et al. (1999) Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol 84: 682-686.
98. Rubenfire, M., McLaughlin, V.V., Allen, R.P., Elliott, G., Park, M.H., Wade, M. et al. (2007) Transition from intravenous epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled Trial. Chest 23(4): 801-834.
99. Rubin, L.J. (1997) Primary pulmonary hypertension. N Engl J Med 336: 111-117.
100. Rubin, L.J., Badesch, D.B., Barst, R.J., Galie, N., Black, C.M., Keogh, A. et al. (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896-903.
101. Rubin, L.J., Mendoza, J., Hood, M., McGoon, M., Barst, R., Williams, W.B. et al. (1990) Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 112: 485-491.
102. Rubin, L.J. and Peter, R.H. (1980) Oral hydralazine therapy for primary pulmonary hypertension. N Engl J Med 302: 69-73.
103. Said, S.I., Hamidi, S.A., Dickman, K.G., Szema, A.M., Lyubsky, S., Lin, R.Z. et al. (2007) Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 115: 1260-1268.
104. Sandoval, J., Gaspar, J., Pulido, T., Bautista, E., Martinez-Guerra, M., Zeballos, M. et al. (1998) Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 32: 297-304.
105. Sandoval, J., Rothman, A. and Pulido, T. (2001) Atrial septostomy for pulmonary hypertension. Clin Chest Med 22: 547-560.
106. Schermuly, R.T., Dony, E., Ghofrani, H.A., Pullamsetti, S., Savai, R., Roth, M. et al. (2005) Reversal of experimental pulmonary hypertension by Pdgf inhibition. J Clin Invest 115: 2811-2821.
107. Schermuly, R.T., Kreisselmeier, K.P., Ghofrani, H.A., Yilmaz, H., Butrous, G., Ermert, L. et al. (2004) Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 169: 39-45.
108. Shapiro, S.M., Oudiz, R.J., Cao, T., Romano, M.A., Beckmann, X.J., Georgiou, D. et al. (1997) Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 30: 343-349.
109. Simonneau, G., Rubin, L.J., Galiè, N., Barst, R.J., Fleming, T.R., Frost, A.E., et al. (2008) Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients With Pulmonary Arterial Hypertension: A Randomized Clinical Trial. Ann Intern Med [in press].
110. Simonneau, G., Barst, R.J., Galie, N., Naeije, R., Rich, S., Bourge, R.C. et al. (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165: 800-804.
111. Sitbon, O., Badesch, D.B., Channick, R.N., Frost, A., Robbins, I.M., Simonneau, G. et al. (2003) Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 124: 247-254.
112. Sitbon, O., Humbert, M., Jagot, J.L., Taravella, O., Fartoukh, M., Parent, F. et al. (1998) Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 12: 265-270.
113. Sitbon, O., Humbert, M., Jais, X., Ioos, V., Hamid, A.M., Provencher, S. et al. (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111: 3105-3111.
114. Sitbon, O., Humbert, M., Nunes, H., Parent, F., Garcia, G., Herve, P. et al. (2002a) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. Prognostic factors and survival. J Am Coll Cardiol 40: 780-788.
115. Sitbon, O., Humbert, M. and Simonneau, G. (2002b) Primary pulmonary hypertension: current therapy. Prog Cardiovasc Dis 45: 115-128.
116. Sitbon, O., Manes, A., Jais, X., Pallazini, M., Humbert, M., Presotto, L. et al. (2007) Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol 49: 1-5.
117. Sitbon, O., McLaughlin, V.V., Badesch, D.B., Barst, R.J., Black, C., Galie, N. et al. (2005) Survival in patients with class Iii idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 60: 1025-1030.
118. Souza, R., Sitbon, O., Parent, F., Simonneau, G. and Humbert, M. (2006) Long term imatinib treatment in pulmonary arterial hypertension. Thorax 61: 736.
119. Tapson, V.F., Gomberg-Maitland, M., McLaughlin, V.V., Benza, R.L., Widlitz, A.C., Krichman, A. et al. (2006) Safety and efficacy of Iv treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 129: 683-688.
120. Upton, P.D., Wharton, J., Coppock, H., Davie, N., Yang, X., Yacoub, M.H. et al. (2001) Adrenomedullin expression and growth inhibitory effects in distinct pulmonary artery smooth muscle cell subpopulations. Am J Respir Cell Mol Biol 24: 170-178.
121. Vachiery, J.L., Hill, N., Zwicke, D., Barst, R., Blackburn, S. and Naeije, R. (2002) Transitioning from I.V. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 121: 1561-1565.
122. Vizza, C.D., Sciomer, S., Morelli, S., Lavalle, C., Di Marzio, P., Padovani, D. et al. (2001) Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart 86: 661-665.
123. Voswinckel, R., Enke, B., Reichenberger, F., Kohstall, M., Kreckel, A., Krick, S. et al. (2006) Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 48: 1672-1681.
124. Woodmansey, P.A., O'toole, L., Channer, K.S. and Morice, A.H. (1996) Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension. Heart 75: 171-173.